Victoria makes Australia’s first mRNA vaccine candidate
Published: 30 November 2021
Victorian scientists and manufacturers have created Australia’s first mRNA COVID-19 vaccine candidate – Australia’s first ever mRNA drug product – in just five months, enabling clinical trials to begin in early 2022.
450 doses of the COVID-19 vaccine candidate have been produced in Boronia in Melbourne’s east, enabling 150 people to take part in Phase 1 clinical trials run by the Doherty Institute in 2022.
The Victorian Government invested $5 million to enable manufacture of the vaccine candidate, with dedicated equipment shipped to manufacturer IDT Australia from Canada. The machine processed nanoparticles into final liquid drug form, sterilised the product and filled vials with mRNA vaccine.
Victoria is one of the few places in the world with the capability to develop and manufacture mRNA therapeutics and vaccines and the mRNA-based vaccine breakthrough demonstrates Victoria’s leadership in the mRNA sector.
The project has been led by mRNA Victoria in partnership with Monash Institute of Pharmaceutical Sciences (MIPS), the Doherty Institute and IDT Australia – a landmark collaboration between Victoria’s renowned medical research and manufacturing sectors.
mRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development, commercialisation and manufacturing investments.